



26 November 2025

Results of Annual General Meeting

Melbourne, Australia, 26 November 2025: dorsaVi Limited (ASX: DVL) (**dorsaVi** or the **Company**) provides the following results of its annual general meeting of shareholders in accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act.

All resolutions were passed on a poll, including resolution 9 which was a special resolution. Details of resolutions, the proxies received, and the votes cast in respect of each resolution are set out in the attached results summary.

– ENDS –

For further information about dorsaVi, please contact:

Gernot Abl

Chairman

+61 419 802 653

Email: ga@dorsavi.com

This announcement was authorised for release by the Board of dorsaVi.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). dorsaVi's Telehealth provides a virtual clinic, enabling clinicians to do business differently and take their patient consultations online. Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com

dorsaVi Limited
2025 Annual General Meeting
Wednesday, 26 November 2025 - Voting Results

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details			Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain	Carried/ Not Carried
1.	Adoption of Remuneration Report	Ordinary	P	374,284,520 99.99%	32,606 0.01%	5,417 0.00%	142,021,605 -	374,289,937 99.99%	32,606 0.01%	265,097 -	Carried
2.	Election of Mr Leigh Travers as a Director of the Company	Ordinary	P	516,203,313 99.98%	91,321 0.02%	5,417 0.00%	44,097 -	516,208,730 99.98%	91,321 0.02%	44,097 -	Carried
3.	Approval to issue Performance Rights to Mr Mathew Regan	Ordinary	P	515,754,760 99.92%	423,943 0.08%	5,417 0.00%	160,028 -	515,760,177 99.92%	423,943 0.08%	160,028 -	Carried
4.	Approval to issue Performance Rights to Mr Ed Doller	Ordinary	P	515,754,760 99.92%	423,943 0.08%	5,417 0.00%	160,028 -	515,760,177 99.92%	423,943 0.08%	160,028 -	Carried
5.	Ratification of prior issue of Placement Shares under Listing Rule 7.1	Ordinary	P	462,782,104 99.91%	431,500 0.09%	7,523 0.00%	53,123,021 -	462,789,627 99.91%	431,500 0.09%	44,097 -	Carried
6.	Ratification of prior issue of Placement Shares under Listing Rule 7.1A	Ordinary	P	462,755,992 99.90%	459,718 0.10%	5,417 0.00%	53,123,021 -	462,761,409 99.90%	459,718 0.10%	44,097 -	Carried
7.	Approval to issue Placement Options	Ordinary	P	462,735,992 99.90%	479,718 0.10%	5,417 0.00%	53,123,021 -	462,741,409 99.90%	479,718 0.10%	44,097 -	Carried
8.	Approval to issue Options to 62 Capital and Evolution Capital	Ordinary	P	462,652,094 99.88%	563,616 0.12%	5,417 0.00%	53,123,021 -	462,657,511 99.88%	563,616 0.12%	53,123,021 -	Carried

9.	Approval of 10% Placement Facility	Special	P	515,736,813 99.89%	557,821 0.11%	5,417 0.00%	44,097 -	515,742,230 99.89%	557,821 0.11%	44,097 -	Carried
10.	Approval to issue Performance Rights to 62 Capital	Ordinary	P	462,665,982 99.88%	549,728 0.12%	5,417 0.00%	53,123,021 -	462,671,399 99.88%	549,728 0.12%	53,123,021 -	Carried
11.	Approval to issue Shares to Dr Andrew Ronchi	Ordinary	P	481,031,252 99.87%	638,943 0.13%	5,417 0.00%	34,668,536 -	481,036,669 99.87%	638,943 0.13%	34,668,536 -	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.